Clinical Trial Update: A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis. [Phase 1]

View source ↗

Summary

A Phase 1 study comparing Ruxolitinib topical cream 1.5% (Taro Pharmaceuticals) with OPZELURA (Ruxolitinib) Cream for mild-to-moderate atopic dermatitis has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• OPZELURA (Ruxolitinib) Cream (ruxolitinib)
• Ruxolitinib topical cream 1.5% (ruxolitinib)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED